Last updated 23 days ago

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

492 patients around the world
Available in Spain, Argentina, United States
Pfizer
1Research sites
492Patients around the world
This study is for people with
Multiple myeloma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Hospital Universitario Austral - Pilar
Av. Juan Domingo Perón 1500, Pilar, Buenos Aires
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy